Table 1 Summary of characteristics of 199,429 eligible participants at baseline.

From: Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank

Probands

 

Unaffected women

Incident EOC patients

199,429

 

198,656

773

Variables

Category

N (%)

N (%)

PVs in six major genes

BRCA1

83 (0.04)

7 (0.91)

BRCA2

405 (0.20)

24 (3.10)

PALB2

277 (0.14)

3 (0.39)

RAD51C

52 (0.03)

3 (0.39)

RAD51D

63 (0.03)

2 (0.26)

BRIP1

309 (0.16)

5 (0.65)

Missing

13,515 (6.80)

50 (6.47)

Parity

Nulliparous

37,498 (18.88)

176 (22.77)

1 birth

26,373 (13.28)

101 (13.07)

2 births

88,274 (44.44)

332 (42.95)

>2 births

46,386 (23.35)

164 (21.22)

Missing

125 (0.06)

0 (0)

Menopausal hormone therapy use

Current C-type

32,588 (16.40)

146 (18.89)

Current E-type

117 (0.06)

4 (0.52)

Former

36,270 (18.26)

181 (23.42)

Never

129,163 (65.02)

440 (56.92)

Missing

518 (0.26)

2 (0.26)

Menopause

Yes

123,516 (62.18)

559 (72.32)

Missing

1 (0)

0 (0)

Age at start of risk prediction

(40, 45)

16,015 (8.07)

25 (3.23)

(45, 50)

27,097 (13.65)

73 (9.44)

(50, 55)

31,643 (15.94)

99 (12.81)

(55, 60)

35,807 (18.03)

126 (16.30)

(60, 65)

46,992 (23.67)

207 (26.78)

(65, 70)

35,644 (17.95)

216 (27.94)

≥70

5458 (2.75)

27 (3.49)

Missing

0 (0)

0 (0)

Mean

57

59

SD

7.97

7.37

Follow-up (years)

Mean

10

6

SD

2

3

Standardised PRS

Mean

0.84

1.13

SD

1.02

1.04

Missing

0 (0)

0 (0)

Duration of oral contraceptive use

Never or <1

6528 (3.29)

28 (3.62)

1–4

30,215 (15.22)

125 (16.17)

5–9

36,359 (18.31)

130 (16.82)

10-14

31,659 (15.94)

100 (12.94)

≥15

41,929 (21.12)

106 (13.71)

Missing

51,966 (26.16)

265 (34.28)

Mean

10.87

9.34

SD

8.04

7.59

Tubal ligation

Yes

1033 (0.52)

4 (0.52)

Missing

0 (0)

0 (0)

Endometriosis

Yes

2007 (1.01)

9 (1.16)

Missing

0 (0)

0 (0)

Height (cm)

Mean

162.7

162.2

SD

6.3

6.3

Missing

391 (0.19)

1 (0.13)

BMI

<18.5

1512 (0.76)

3 (0.48)

(18.5, 25)

80,143 (40.34)

289 (37.25)

(25, 30)

72,107 (36.30)

288 (38.81)

≥30

44,311 (22.31)

190 (24.58)

Missing

583 (0.29)

3 (0.48)

  1. MHT menopause hormone therapy, PRS polygenic risk score, BMI body mass index, SD standard deviation.